Abbott Laboratories (ABT) : Welch Forbes scooped up 2,438 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 2, 2016. The investment management firm now holds a total of 652,227 shares of Abbott Laboratories which is valued at $29,317,604.Abbott Laboratories makes up approximately 0.87% of Welch Forbes’s portfolio.
Other Hedge Funds, Including , Smith Chas P Associates Pa Cpas reduced its stake in ABT by selling 7,049 shares or 9.35% in the most recent quarter. The Hedge Fund company now holds 68,326 shares of ABT which is valued at $3,071,254. Abbott Laboratories makes up approx 0.51% of Smith Chas P Associates Pa Cpas’s portfolio.Ramsay Stattman Vela Price boosted its stake in ABT in the latest quarter, The investment management firm added 24,110 additional shares and now holds a total of 137,045 shares of Abbott Laboratories which is valued at $5,984,755. Abbott Laboratories makes up approx 2.88% of Ramsay Stattman Vela Price’s portfolio.Dynamic Advisors Solutions boosted its stake in ABT in the latest quarter, The investment management firm added 840 additional shares and now holds a total of 14,115 shares of Abbott Laboratories which is valued at $609,345. Abbott Laboratories makes up approx 0.24% of Dynamic Advisors Solutions’s portfolio.New England Research Management boosted its stake in ABT in the latest quarter, The investment management firm added 15,900 additional shares and now holds a total of 31,027 shares of Abbott Laboratories which is valued at $1,223,705. Abbott Laboratories makes up approx 1.07% of New England Research Management’s portfolio.
Abbott Laboratories closed down -0.24 points or -0.53% at $45.02 with 76,57,947 shares getting traded on Monday. Post opening the session at $45.06, the shares hit an intraday low of $44.88 and an intraday high of $45.41 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.